Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 2 of a two-part series examining new research on the proposed RSV vaccine.
 
The GameChanger
RSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in pregnant patients may help newborns.
 
Show Segments
00:00 - Introductions
02:57 - Recap From Part 1
06:45 - Looking at the MATISSE Study
14:17 - The GameChanger: MATISSE Results
22:27 - Connecting to Practice: Barriers to Applying
31:05 - Closing Remarks
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
Jake Galdo, PharmD, MBA, BCPS, BCGP
Managing Network Facilitator, CPESN Health Equity
CEO, Seguridad

Reference
Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
 

CE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the MATISSE study in relation to RSV vaccines
2. Describe barriers to applying the information in this study to general populations

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-193-H06-P
Initial release date: 05/08/2023
Expiration date: 05/08/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram